archive-com.com » COM » E » ENDEAVOURVISION.COM

Total: 462

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • BIND Recognized by the World Economic Forum as a Technology Pioneer
    BIND 014 is an Accurin that targets PSMA and contains docetaxel a clinically validated and widely used cancer chemotherapy drug BIND 014 is currently in Phase 2 clinical trials for non small cell lung cancer and metastatic castrate resistant prostate cancer To date in 2013 BIND has announced collaborations with Amgen Inc Pfizer Inc and AstraZeneca AB to develop Accurins based on therapeutic payloads from their product pipelines BIND s platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women s Hospital Harvard Medical School of BIND s scientific founders and directors Dr Robert Langer and Dr Omid Farokhzad For more information please visit the company s web site at www bindtherapeutics com Media Gina Nugent The Yates Network 617 460 3579 gina theyatesnetwork com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those who understand your business and embrace your vision Those who know how to challenge your execution and to bring value This is why I recommend Endeavour Vision team to entrepreneurs looking for funding

    Original URL path: http://www.endeavourvision.com/news-n202-c72-BIND+Recognized+by+the+World+Economic+Fo.htm (2016-04-25)
    Open archived version from archive


  • BIND Doses First Patient in a Phase 2 Clinical Study of BIND-014 in Prostate Cancer
    cancer For more specific information on the trial including patient eligibility and clinical trial endpoints please visit www clinicaltrials gov NCT01812746 BIND 014 represents the first Accurin nanomedicine to reach the clinic from BIND s Medicinal Nanoengineering platform BIND 014 targets PSMA a target expressed on prostate cancer cells and the blood vessels of many types of non prostate solid tumors and contains docetaxel a clinically validated and widely used chemotherapy drug Docetaxel is currently FDA approved for the treatment of breast cancer non small cell lung cancer metastatic castrate resistant prostate cancer head and neck cancer and gastric cancer About Accurins Accurins are BIND s targeted and programmable therapeutics which are designed utilizing BIND s medicinal nanoengineering platform with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues Accurins are polymeric nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation within the bloodstream enable targeting of the diseased tissue or cells and provide for the controlled and timely release of the therapeutic payload BIND has demonstrated in preclinical studies that Accurins can improve tumor growth suppression achieve higher concentrations of the payload in tumors compared to the payload administered in conventional form and have pharmacokinetics and tolerability differentiated from their therapeutic payloads About BIND Therapeutics BIND Therapeutics is a clinical stage nanomedicine platform company developing Accurins its novel targeted therapeutics BIND intends to leverage its medicinal nanoengineering platform to develop a pipeline of Accurins initially in oncology as well as Accurins in collaboration with biopharmaceutical companies BIND s lead drug candidate BIND 014 is an Accurin that targets PSMA and contains docetaxel a clinically validated and widely used cancer chemotherapy drug BIND 014 is currently in Phase 2 clinical trials for non small cell lung cancer and metastatic castrate resistant prostate cancer To date in 2013 BIND has announced collaborations with Amgen Inc Pfizer Inc and AstraZeneca AB to develop Accurins based on therapeutic payloads from their product pipelines BIND s platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women s Hospital Harvard Medical School of BIND s scientific founders and directors Dr Robert Langer and Dr Omid Farokhzad For more information please visit the company s web site at www bindtherapeutics com Media Gina Nugent The Yates Network Tel 617 460 3579 gina theyatesnetwork com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and

    Original URL path: http://www.endeavourvision.com/news-n197-c72-BIND+Doses+First+Patient+in+a+Phase+2+Cl.htm (2016-04-25)
    Open archived version from archive

  • BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering
    the Credit Suisse Prospectus Department One Madison Avenue New York NY 10010 Telephone 800 221 1037 Email newyork prospectus credit suisse com and from Cowen and Company LLC c o Broadridge Financial Services Attention Prospectus Department 1155 Long Island Avenue Edgewood NY 11717 Telephone 631 274 2806 Fax 631 254 7140 A registration statement relating to these securities has been filed with the SEC but has not yet become effective These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction About BIND Therapeutics BIND Therapeutics is a clinical stage nanomedicine platform company developing Accurins its novel targeted therapeutics BIND intends to leverage its medicinal nanoengineering platform to develop a pipeline of Accurins initially in oncology as well as Accurins in collaboration with biopharmaceutical companies BIND s lead drug candidate BIND 014 is an Accurin that targets PSMA and contains docetaxel a clinically validated and widely used cancer chemotherapy drug BIND 014 is currently in Phase 2 clinical trials for non small cell lung cancer and metastatic castrate resistant prostate cancer BIND has announced collaborations with Amgen Inc Pfizer Inc and AstraZeneca AB to develop Accurins based on therapeutic payloads from their product pipelines BIND s platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women s Hospital Harvard Medical School of BIND s scientific founders and directors Dr Robert Langer and Dr Omid Farokhzad back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those who understand your business and embrace your vision Those who know how to challenge your execution and to bring value This is why I recommend Endeavour Vision team to entrepreneurs looking for funding Dr Georges Karam co Founder President CEO Sequans With Endeavour Vision we have been able to establish at fast speed the personal trust level needed and also come to terms

    Original URL path: http://www.endeavourvision.com/news-n194-c72-BIND+Therapeutics+Files+Registration+Sta.htm (2016-04-25)
    Open archived version from archive

  • BIND Therapeutics and AstraZeneca Announce Worldwide Development and Commercialization Agreement for Cancer Nanomedicine
    development AstraZeneca believes that targeted therapies which specifically address the underlying mechanisms of disease are the future of personalized cancer treatment said Susan Galbraith Head of AstraZeneca s Oncology Innovative Medicines Unit Our oncology teams are actively exploring a range of platforms to deliver targeted therapies with a strategic focus on unlocking the significant potential of nanoparticles as an approach to cancer treatment We view BIND s targeted nanomedicines as a leading technology in this field About Accurins BIND Therapeutics is discovering and developing Accurins proprietary new best in class therapeutics with superior target selectivity and the potential to improve patient outcomes in the areas of oncology inflammatory diseases and cardiovascular disorders Leveraging its proprietary Medicinal Nanoengineering platform BIND develops Accurins that outperform conventional drugs by selectively accumulating in diseased tissues and cells The result is higher drug concentrations at the site of action with minimal off target exposure leading to markedly better efficacy and safety About BIND Therapeutics BIND Therapeutics is a clinical stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins BIND s Medicinal Nanoengineering platform enables the design engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites dramatically enhancing efficacy while minimizing toxicities BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best in class drugs and improve patient outcomes in the areas of oncology inflammatory diseases and cardiovascular disorders BIND s lead product candidate BIND 014 is currently entering Phase 2 clinical testing in cancer patients and is designed to selectively target PSMA a surface protein upregulated in a broad range of solid tumors BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products BIND is backed by leading investors Polaris Venture Partners Flagship Ventures ARCH Venture Partners NanoDimension DHK Investments EndeavourVision and Rusnano BIND was founded on proprietary technology from the laboratories of two leaders in the field of nanomedicine Professors Robert Langer David H Koch Institute Professor of the Massachusetts Institute of Technology MIT and Omid Farokhzad Associate Professor of Harvard Medical School For more information please visit the company s web site at www bindtherapeutics com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more

    Original URL path: http://www.endeavourvision.com/news-n181-c72-BIND+Therapeutics+and+AstraZeneca+Announ.htm (2016-04-25)
    Open archived version from archive

  • BIND Therapeutics Announces Global Collaboration with Pfizer to Develop and Commercialize Multiple Accurins
    pharmaceutical industry Pfizer has a strong legacy in targeted small molecule drug discovery and development and continues to be on the cutting edge of innovation in this area said Rod MacKenzie Senior Vice President and Head of PharmaTherapeutics R D at Pfizer We look forward to working with the team at BIND Therapeutics to create targeted Accurins with the aim of optimizing the therapeutic potential of future small molecules About Accurins BIND Therapeutics is discovering and developing Accurins proprietary new best in class therapeutics with superior target selectivity and the potential to improve patient outcomes in the areas of oncology inflammatory diseases and cardiovascular disorders Leveraging its proprietary Medicinal Nanoengineering platform BIND develops Accurins that outperform conventional drugs by selectively accumulating in diseased tissues and cells The result is higher drug concentrations at the site of action with minimal off target exposure leading to markedly better efficacy and safety About BIND Therapeutics BIND Therapeutics is a clinical stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins BIND s Medicinal Nanoengineering platform enables the design engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites dramatically enhancing efficacy while minimizing toxicities BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best in class drugs and improve patient outcomes in the areas of oncology inflammatory diseases and cardiovascular disorders BIND s lead product candidate BIND 014 is currently entering Phase 2 clinical testing in cancer patients and is designed to selectively target a surface protein upregulated in a broad range of solid tumors BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products BIND is backed by leading investors Polaris Venture Partners Flagship Ventures ARCH Venture Partners NanoDimension DHK Investments EndeavourVision and Rusnano BIND was founded on proprietary technology from the laboratories of two leaders in the field of nanomedicine Professors Robert Langer David H Koch Institute Professor of the Massachusetts Institute of Technology MIT and Omid Farokhzad Associate Professor of Harvard Medical School For more information please visit the company s web site at www bindtherapeutics com Contacts The Yates Network Kathryn Morris 845 635 9828 Kathryn theyatesnetwork com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project

    Original URL path: http://www.endeavourvision.com/news-n179-c72-BIND+Therapeutics+Announces+Global+Colla.htm (2016-04-25)
    Open archived version from archive

  • BIND Biosciences and Amgen Sign Agreement For The Worldwide Development and Commercialization of a Kinase Inhibitor Nanomedicine
    with Amgen s focus on the development of highly targeted and selective oncology therapeutics said Joseph P Miletich M D Ph D senior vice president of Research and Development at Amgen We look forward to collaborating with the BIND scientific team to leverage this technology to address unmet medical needs of cancer patients We are pleased to collaborate with Amgen an industry leader with a proven track record of success in oncology on extending our technology into molecularly targeted drugs such as kinase inhibitors said Scott Minick CEO of BIND Through this collaboration Amgen has recognized the unique potential of BIND s Medicinal Nanoengineering platform to create programmable oncology therapeutics that combine molecular and tissue targeting for unsurpassed selectivity and activity About BIND Biosciences BIND Biosciences is a clinical stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM BIND s Medicinal Nanoengineering platform enables the design engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites dramatically enhancing efficacy while minimizing toxicities BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best in class drugs and improve patient outcomes in the areas of oncology inflammatory diseases and cardiovascular disorders BIND s lead product candidate BIND 014 is currently in Phase 1 clinical testing in cancer patients and is designed to selectively target a surface protein upregulated in a broad range of solid tumors BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products BIND is backed by leading investors Polaris Venture Partners Flagship Ventures ARCH Venture Partners NanoDimension DHK Investments EndeavourVision and Rusnano BIND was founded on proprietary technology from the laboratories of two leaders in the field of nanomedicine Professors Robert Langer David H Koch Institute Professor of the Massachusetts Institute of Technology MIT and Omid Farokhzad Associate Professor of Harvard Medical School For more information please visit the company s web site at www bindbio com Media Contact Kathryn Morris The Yates Network 845 635 9828 kathryn theyatesnetwork com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those

    Original URL path: http://www.endeavourvision.com/news-n174-c72-BIND+Biosciences+and+Amgen+Sign+Agreemen.htm (2016-04-25)
    Open archived version from archive

  • BIND Is Granted Five U.S. Patents Covering BIND-014 and Accurin(TM) Platform
    patents acknowledges the innovative nature of our platform and products as well as the proprietary methods we use to produce them We expect additional patent issuances over the coming months continuing to further bolster this broad and growing patent estate said Scott Minick CEO of BIND We are highly encouraged by the real world impact of our innovative technology embodied in BIND 014 our lead Accurin product candidate which is showing promising clinical results for solid tumors About BIND Biosciences BIND Biosciences is a clinical stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins TM BIND s Medicinal Nanoengineering TM platform enables the design engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites dramatically enhancing efficacy while minimizing toxicities BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best in class drugs and improve patient outcomes in the areas of oncology inflammatory diseases and cardiovascular disorders BIND s lead product candidate BIND 014 is currently in Phase 1 clinical testing in cancer patients and is designed to selectively target a surface protein upregulated in a broad range of solid tumors BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products BIND is backed by leading investors Polaris Venture Partners Flagship Ventures ARCH Venture Partners NanoDimension DHK Investments EndeavourVision and Rusnano BIND was founded on proprietary technology from the laboratories of two leaders in the field of nanomedicine Professors Robert Langer David H Koch Institute Professor of the Massachusetts Institute of Technology MIT and Omid Farokhzad Associate Professor of Harvard Medical School For more information please visit the company s web site at www bindbio com SOURCE BIND Biosciences back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those who understand your business and embrace your vision Those who know how to challenge your execution and to bring value This is why I recommend Endeavour Vision team to entrepreneurs looking for funding Dr Georges Karam co Founder President CEO Sequans With Endeavour Vision we have been able to establish at fast

    Original URL path: http://www.endeavourvision.com/news-n166-c72-BIND+Is+Granted+Five+U.S.+Patents+Coveri.htm (2016-04-25)
    Open archived version from archive

  • BIND Biosciences appoints Andrew J. Hirsch as Chief Financial Officer
    recently as Vice President Corporate Strategy and M A where he played a key role in developing a new strategy for the company and evaluating M A opportunities Prior to that Mr Hirsch held various positions in the finance organization including leading the company s Business Planning and Investor Relations functions Prior to joining Biogen Idec Mr Hirsch led business development for a software start up company and spent several years in management consulting at both Stern Stewart Co and The Parthenon Group He holds a Masters of Business Administration from the Tuck School at Dartmouth College and a Bachelor of Arts in Economics from the University of Pennsylvania About BIND Biosciences BIND Biosciences is a clinical stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM BIND s Medicinal NanoengineeringTM platform enables the design engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites dramatically enhancing efficacy while minimizing toxicities BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best in class drugs and improve patient outcomes in the areas of oncology inflammatory diseases and cardiovascular disorders BIND s lead product candidate BIND 014 is currently in Phase 1 clinical testing in cancer patients and is designed to selectively target a surface protein upregulated in a broad range of solid tumors BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products BIND is backed by leading investors Polaris Venture Partners Flagship Ventures ARCH Venture Partners NanoDimension DHK Investments EndeavourVision and Rusnano BIND was founded on proprietary technology from the laboratories of two leaders in the field of nanomedicine Professors Robert Langer David H Koch Institute Professor of the Massachusetts Institute of Technology MIT and Omid Farokhzad Associate Professor of Harvard Medical School For more information please visit the company s web site at www bindbio com Contacts Media Gina Nugent The Yates Network 1 617 460 3579 back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those who understand your business and embrace your vision Those who know how to challenge

    Original URL path: http://www.endeavourvision.com/news-n159-c72-BIND+Biosciences+appoints+Andrew+J.+Hirs.htm (2016-04-25)
    Open archived version from archive



  •